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Background and aims: Statin treatment disrupts HMG-CoA reductase-mediated endogenous cholesterol
synthesis and lowers plasma LDL-cholesterol levels. Although statin treatment can theoretically impair
adrenal steroid hormone synthesis, thus far, no effect on glucocorticoid output has been described, as
LDL-cholesterol levels usually remain within the physiological range. However, novel statin-based
treatment regimens that dramatically decrease LDL-cholesterol levels are currently employed. Here,
we assessed whether inhibition of cholesterol synthesis under these relatively hypocholesterolemic
conditions may alter adrenal glucocorticoid output.
Methods: Hypocholesterolemic apolipoprotein A1 (apoA1) knockout mice were administered high dose
simvastatin twice daily for 3 days.
Results: Simvastatin treatment did not change plasma cholesterol levels or modify the adrenal expres-
sion levels of genes involved in cholesterol metabolism. However, simvastatin treatment lowered basal
plasma levels of the primary glucocorticoid corticosterone (62%; p < 0.05). Upon injection with adre-
nocorticotropic hormone, control-treated apoA1 knockout mice already showed only a mild increase in
plasma corticosterone levels, indicative of relative glucocorticoid insufﬁciency. Importantly, simvastatin
treatment further diminished the adrenal glucocorticoid response to adrenocorticotropic hormone
exposure (two-way ANOVA p < 0.05 for treatment). Peak corticosterone levels were 49% lower (p < 0.01)
upon simvastatin treatment.
Conclusions: We have shown that simvastatin treatment aggravates the glucocorticoid insufﬁciency
associated with hypocholesterolemia in mice. Our data suggest that (1) HMG-CoA reductase activity
controls the adrenal steroidogenic capacity under hypocholesterolemic conditions and (2) imply that it
might be important to monitor adrenal function in humans subjected to statin-based treatments aimed
at achieving sub-physiological LDL-cholesterol levels, as these may potentially execute a negative impact
on the glucocorticoid function in humans.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Glucocorticoids, through an interaction with their cognate nu-
clear glucocorticoid receptor, modulate a great variety of physio-
logical processes, including glucose metabolism and inﬂammation.
High levels of glucocorticoids are secreted by adrenals in response
to activation of the hypothalamus-pituitary-adrenal axis totics, Cluster BioTherapeutics,
Laboratories, Einsteinweg 55,
Hoekstra).
r Ireland Ltd. This is an open accesfacilitate the physiological response to stress [1]. In line with the
importance of glucocorticoids in normal physiology, subjects
suffering from glucocorticoid insufﬁciency, i.e. Addison's disease
patients, display an overall increased risk for mortality [2].
Glucocorticoids, such as cortisol in humans and corticosterone
in mice, are synthesized from their common precursor cholesterol.
Several lines of evidence have suggested that adrenal de novo
cholesterol synthesis does not contribute to the generation of the
steroidogenic cholesterol pool under normolipidemic conditions.
More speciﬁcally, studies in rats have shown that activity of the
HMG-CoA reductase, the rate-limiting enzyme in de novo choles-
terol synthesis, within the adrenals is relatively low as long as
cholesterol can be obtained from lipoproteins in the plasmas article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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reductase can be detected in adrenals of wild-type mice [3]. As
such, lipoproteins should be regarded as the primary source of
cholesterol used for glucocorticoid production by the adrenals.
From in vivo studies, it has become apparent that low-density
lipoprotein (LDL) as compared to high-density lipoprotein (HDL)
is the preferred lipoprotein substrate for the adrenals in humans.
Human HDL deﬁciency or lack of a functional HDL receptor is
associated with a decreased urinary cortisol concentration [7,8]. In
addition, plasma HDL-cholesterol levels correlate with the
synacthen-induced cortisol response in critically ill patients [9].
HDL may therefore also contribute, at least a bit, to adrenal
glucocorticoid synthesis in humans. However, HDL-cholesterol is
not able to compensate for a lack of cholesterol associated with LDL
particles in humans. As a result, LDL deﬁcient abetalipoproteinemic
patients, that contain relatively normal amounts of HDL-
cholesterol, suffer from glucocorticoid insufﬁciency [11e13]. In
further support of a limited relevance of HDL in the supply of
cholesterol to the adrenal steroidogenic machinery, HDL is redun-
dant for adrenal steroidogenesis in mice with a human-like, LDL-
rich, lipoprotein phenotype [10].
LDL-cholesterol lowering, i.e. through statin therapy, is the ﬁrst
treatment goal in high-risk cardiovascular disease patients, given
that the presence of relatively high plasma levels of cholesterol
associated with LDL is an established risk factor for the develop-
ment of atherosclerotic lesions [14]. A ~30% cardiovascular disease
risk reduction is generally achieved through statin treatment [15],
which shows the success of the application of statins as LDL-
cholesterol lowering drugs in clinical practice. Despite the fact
that the adrenals acquire the majority of the cholesterol used for
glucocorticoid synthesis from LDL particles, thus far, statin treat-
ment has not shown to execute amajor effect on the adrenal steroid
output in humans [16e22]. It should, however, be acknowledged
that LDL-cholesterol levels usually remain within the normal
physiological range in response to classical statin therapies, as they
mostly have been applied to reverse (excessive) hypercholester-
olemia. In contrast, novel cardiovascular therapeutic approaches,
e.g., anti-proprotein convertase subtilisin/kexin type 9 (PCSK9)
antibody/statin co-treatment and ezetimibe/statin co-treatment,
aim to create a treatment condition of relative hypocholester-
olemia, i.e., in which the amount of LDL-cholesterol in the blood
circulation is actually lower than that of normolipidemic subjects
[23,24].
Hypocholesterolemic mice as compared to normolipidemic
wild-type mice display a marked increase in adrenal relative mRNA
expression levels of HMG-CoA reductase, which translates into a
signiﬁcant rise in adrenal HMG-CoA reductase activity [3,5]. It thus
appears that when relatively low amounts of cholesterol can be
acquired from lipoproteins, adrenal de novo cholesterol synthesis is
activated in an attempt to overcome cholesterol insufﬁciency.
Based upon this notion, it can be anticipated that de novo choles-
terol synthesis also makes a signiﬁcant contribution to the gener-
ation of the steroidogenic cholesterol pool in humans subjected to
the aggressive LDL-cholesterol lowering therapies, such as high
dose statin/PCSK9 inhibitor (combination) treatment. Statins
execute their cholesterol-lowering effect by inhibiting HMG-CoA
reductase activity, which leads to an upregulation of LDL re-
ceptors and a concomitant increase in the clearance of LDL particles
from the blood circulation by the liver. Importantly, studies in mice
have suggested that statin treatment not only diminishes hepatic
cholesterol synthesis, but also signiﬁcantly inhibits the incorpora-
tion of acetate into lipids within the adrenals [28]. When applied in
aggressive LDL-cholesterol lowering combination therapies, statins
may, therefore, also disrupt the (compensatory) increase in adrenal
cholesterol synthesis induced by relative hypocholesterolemia,theoretically resulting in an impairment of the adrenal glucocor-
ticoid function.
Here we aimed to provide experimental proof for our working
hypothesis that statin-mediated suppression of adrenal de novo
cholesterol synthesis will affect glucocorticoid output under
hypocholesterolemic conditions. To this purpose, we subjected
genetically hypocholesterolemic mice to simvastatin treatment and
investigated the adrenal glucocorticoid function.
2. Materials and methods
2.1. Experimental mice and treatment
Apolipoprotein A1 (apoA1) x LDL receptor (ldlr) double knockout
mice were obtained from Dr. Jan Albert Kuivenhoven from the
Department of Experimental Vascular Medicine, Academic Medical
Centre, Amsterdam. Male double knockout mice were mated with
female C57BL/6 mice to generate double heterozygous offspring,
which was intercrossed to ultimately derive apoA1 single knockout
mice that were inbred for further expansion of the colony. Animal
experiments were performed in a temperature and light cycle (12 h
light/12 h dark) controlled room at the Gorlaeus Laboratories of the
Leiden Academic Centre for Drug Research, in accordance with the
National Laws. All experimental protocols were approved by the
Ethics Committee for Animal Experiments of Leiden University.
Male apoA1 knockout mice (13e18 weeks old; ~30 g) were
single housed for 1.5 weeks preluding as well as during the
experiment. All mice had continuous free access to food and water.
Simvastatin was obtained in tablets from Pharmachemie (Haarlem,
The Netherlands). Tablets were crushed with a mortar and pestle
and subsequently dissolved in tap water. Age-matched groups of
apoA1 knockout mice (N ¼ 9 per group) were orally administered
twice a day 250 ml of water either with or without 100 mg/kg body
weight simvastatin supplementation for 3 days, with the ﬁnal dose
given at 9:00 AM [25]. Two hours after the ﬁnal dosing, all mice
were bled via tail tip cut for plasma cholesterol and basal cortico-
sterone measurements. Subsequently, mice were administered
200 mg of adrenocorticotropic hormone (ACTH; MT-Diagnostics,
Etten-Leur, The Netherlands) intraperitoneally to stimulate the
adrenal glucocorticoid output [26]. One and two hours after ACTH
injection, tail blood samples were obtained for corticosterone
measurement and/or hematological analysis. During blood draws,
mice were handled identically and restrained for a maximum of
30 s to exclude an impact on blood corticosterone levels. Mice were
sacriﬁced through cervical dislocation and organs were harvested.
Adrenals and livers of all mice were isolated within 30 min, i.e.,
maximally 2.5 h and 4.5 h after the administration of ACTH and the
ﬁnal dose of simvastatin, respectively, and stored at 20 C until
further use.
2.2. Plasma cholesterol analysis
Concentrations of free and total cholesterol were determined in
plasma obtained from tail blood using enzymatic colorimetric as-
says (Roche Diagnostics).
2.3. Plasma corticosterone analysis
Corticosterone levels were determined in tail blood plasma us-
ing the [3H] radioactive kit from MP Biomedicals (Irvine, CA).
2.4. Analysis of gene expression by real-time quantitative PCR
Quantitative gene expression analysis on livers and adrenals
was performed as described [27]. In short, total RNA was isolated
Fig. 1. The effect of simvastatin treatment on hepatic relative expression levels of the
LDL receptor (ldlr) and HMG-CoA reductase (hmgcr) in apoA1 knockout mice.
Beta-actin, glyceraldehyde-3-phosphate dehydrogenase, ribosomal protein L27, and
peptidylprolyl isomerase A (PPIA) were used as housekeeping genes for normalization.
Data represent means ±SEM of 8e9 mice per group. ***p < 0.001 versus Control.
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transcribed with RevertAid™ reverse transcriptase. Gene expres-
sion analysis was performed using real-time SYBR Green technol-
ogy (Eurogentec). Primers were validated for identical efﬁciencies.
Primer sequences are available upon request. Beta-actin, glyceral-
dehyde-3-phosphate dehydrogenase, ribosomal protein L27, and
peptidylprolyl isomerase A were used as standard housekeeping
genes in both liver and adrenal gene expression analyses. Relative
expression levels were calculated by subtracting the cycle
threshold number (Ct) from the gene of interest from the average
housekeeping Ct and raising 2 to the power of this difference. No
signiﬁcant difference in the housekeeping Ct values was observed
between the two experimental groups.
2.5. Data analysis
Statistical analysis was performed using Graphpad Instat soft-
ware (San Diego, USA, http://www.graphpad.com). Normality
testing of the experimental groups was performed using the
method of Kolmogorov and Smirnov. Signiﬁcance was calculated
using a two-tailed Student's t-test or two-way analysis of variance
(ANOVA) with Bonferroni post-test where appropriate. Probability
values less than 0.05 were considered signiﬁcant.
3. Results
Previous studies using gene knockout mice have indicated that,
probably since HDL is the predominant lipoprotein species circu-
lating in murine plasma, HDL represents the major source of
cholesterol utilized for glucocorticoid synthesis in mice [3,5,6].
Genetic deletion of apolipoprotein A1 (apoA1) expression in mice is
associated with marked hypocholesterolemia due to HDL deﬁ-
ciency [3]. To identify a potential effect on steroidogenesis of statin-
mediated disruption of adrenal de novo cholesterol synthesis under
hypocholesterolemic conditions, we determined the impact of
simvastatin treatment on the glucocorticoid function of apoA1
deﬁcient mice. Simvastatin was chosen for our studies, since this
statin species appears to be most effective in targeting adrenals
in vivo [28]. Koga et al. previously observed that treatment of mice
with a single oral dose of 20 mg/kg simvastatin reduces adrenal
HMG-CoA reductase activity by 40e50% [28]. With the aim to
achieve a maximal extent of adrenal de novo cholesterol synthesis
inhibition, we applied an oral dosing regimen of simvastatin
100 mg/kg twice daily for 3 days [25] in our apoA1 knockout mouse
model.
Schonewelle et al. have previously shown that, in C57Bl/6 wild-
type mice, statin-induced inhibition of HMG-CoA reductase activity
is associated with a compensatory increase in the hepatic mRNA
expression of genes involved in cholesterol acquisition and syn-
thesis [29]. As can be appreciated from Fig. 1, we also observed a
signiﬁcant rise in LDL receptor mRNA expression (þ39%; p < 0.001)
in livers of our apoA1 knockout mice upon simvastatin treatment.
Furthermore, a 45% higher mRNA expression of HMG-CoA reduc-
tase was detected in livers from simvastatin-treated apoA1
knockout mice as compared to those from water devoid of simva-
statin control-treated apoA1 knockout mice (Fig. 1). Although this
latter effect did not reach statistical signiﬁcance due to the large
intra-group variation (p ¼ 0.07), it can be anticipated that in our
current experimental setup simvastatin, indeed, effectively inhibi-
ted HMG-CoA reductase activity.
In contrast to the potent lipid-lowering effect of simvastatin
observed in humans [30], simvastatin treatment did not impact on
the extent of hypocholesterolemia. Simvastatin-treated apoA1
knockout mice exhibited free and total cholesterol levels of
11 ± 1 mg/dl and 28 ± 2 mg/dl, while these respective levels were10 ± 1 mg/dl and 30 ± 3 mg/dl in control apoA1 knockout mice
orally administered the solvent only. A potential difference in the
steroidogenic capacity of the adrenals in response to simvastatin
exposure cannot be attributed to a change in exogenous substrate
availability.
Since an efﬁcient (intra)cellular mobilization of cholesterol by
the adrenals is essential for glucocorticoid synthesis [6,31,32], we
veriﬁed whether simvastatin treatment affected the adrenal
expression levels of genes involved in cholesterol homeostasis. As
evident from Fig. 2, no signiﬁcant change in the relative transcript
abundance of the scavenger receptor BI (sr-bi), the LDL receptor
(ldlr), or HMG-CoA reductase (hmgcr) was observed in response to
simvastatin treatment. A direct effect of simvastatin on adrenal
lipoprotein-cholesterol uptake and de novo cholesterol synthesis
can thus be considered highly unlikely. Relative mRNA expression
levels of the ATP-binding cassette transporter A1 (abca1) and
apolipoprotein E (apoE) were equal within the two groups, sug-
gesting a similar rate of cholesterol efﬂux from adrenocortical cells
to apoE-containing HDL-like particles. Notably, as judged from the
unchanged expression levels of steroidogenic acute regulatory
protein (star), mitochondria localized glutamic acid rich protein
(hummr/mgarp), and cytochrome P450 family 11 subfamily A
member 1 (cyp11a1), simvastatin treatment did not impact on the
intracellular trafﬁcking of free cholesterol between the endo-
plasmatic reticulum and mitochondria or the actual conversion of
cholesterol into steroids.
Plasma levels of the primary glucocorticoid species corticoste-
rone are normally ~100 ng/ml in the basal state and increase rapidly
to levels >250 ng/ml in response to stress in normolipidemic wild-
type mice [3,5,6,31]. In agreement with the ﬁndings of Plump et al.
that apoA1 deﬁcient mice as compared to wild-type mice show a
reduced (basal) steroidogenesis rate [3], basal levels of corticoste-
rone were 31 ± 9 ng/ml in our water-treated apoA1 knockout mice
(Fig. 3A). Strikingly, despite the already low levels in the control
condition, simvastatin treatment was able to further decrease
baseline corticosterone values (62% vs. control-treated mice;
p < 0.05; Fig. 3A).
Fig. 2. The effect of simvastatin treatment on relative expression levels of genes
involved in cholesterol uptake (sr-bi/ldlr) and synthesis (hmgcr), intracellular traf-
ﬁcking (star/hummr), and efﬂux (abca1/apoE) and metabolism of cholesterol to steroids
(cyp11a1) in adrenals from apoA1 knockout mice.
Beta-actin, glyceraldehyde-3-phosphate dehydrogenase, ribosomal protein L27, and
peptidylprolyl isomerase A (PPIA) were used as housekeeping genes for normalization.
Data represent means ±SEM of 8e9 mice per group.
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potent endogenous activator of adrenal glucocorticoid production
and an ACTH challenge is, therefore, an appropriate method to
measure the maximal adrenal glucocorticoid output in mice [5,26].
Control apoA1 knockout mice displayed a marked rise in plasma
corticosterone levels as compared to baseline, at one hour after
ACTH injection, which was, however, completely abrogated one
hour later. In light of the fact that wild-type mice display a maximal
plasma corticosterone level over a period of at least three hours in
response to an ACTH challenge [5], this ﬁnding provides additional
proof of a generally low maximal steroidogenic capacity of apoA1
knockout adrenals [3]. Importantly, as evident from Fig. 3B, the
one-hour plasma peak value of corticosterone was 49% lower in
simvastatin-treated mice as compared to controls (two-way
ANOVA Bonferroni post-test: p < 0.01).Fig. 3. The effect of simvastatin treatment on the adrenal glucocorticoid function in apoA1
(A) Basal plasma corticosterone levels and (B) the corticosterone response to an ACTH cha
Control.4. Discussion
In the current study, we evaluated the effect of statin treatment
on the adrenal glucocorticoid output under hypocholesterolemic
conditions in mice. Our data conﬁrm previous observations that
hypocholesterolemia, i.e., HDL deﬁciency, in mice is associated with
an impaired adrenal glucocorticoid response to stress [3,5,33].
Given that ACTH treatment was able to induce only a short-term
(<2 h) and rather limited rise in plasma corticosterone levels in
our HDL deﬁcient apoA1 knockout mice, lipoprotein-associated
cholesterol should deﬁnitely be regarded as the primary steroido-
genic cholesterol source.
Here we have shown that simvastatin-induced inhibition of
HMG-CoA reductase activity in apoA1 knockoutmice translates into
a >60% decrease in basal plasma corticosterone levels and amarked
impairment to respond to an established steroidogenic trigger, e.g.,
ACTH exposure. We have not been able to measure the actual
extent of inhibition of adrenal HMG-CoA reductase activity in
response to simvastatin treatment. Although, based on previously
published studies [28], we are conﬁdent that we achieved at least a
50% reduction in adrenal HMG-CoA reductase activity through
simvastatin treatment, it is fair to anticipate that we did not
completely block enzyme activity in the adrenals. This can explain
why our simvastatin-treated animals were still able to increase
their plasma corticosterone level, albeit to a relatively very low
extent, upon ACTH exposure. Nevertheless, our data clearly indicate
that intra-adrenal cholesterol synthesis contributes signiﬁcantly to
the generation of the steroidogenic cholesterol pool in a lipoprotein
deﬁciency context as simvastatin treatment markedly reduced both
the basal and maximal adrenal glucocorticoid output in apoA1
knockout mice.
The decrease in glucocorticoid output upon simvastatin treat-
ment was not due to a decrease in exogenous substrate availability
as the extent of hypocholesterolemia was identical in the two
groups of apoA1 knockout mice. The absence of an effect on plasma
cholesterol levels was to be expected, since statin treatment
generally does not impact on plasma total cholesterol levels in mice
[34]. Since statin treatment does lower LDL-cholesterol levels in
humans, one could argue that the absence of a lipid-lowering effect
in response to simvastatin treatment makes it hard to translate our
ﬁndings from mice to the human situation. However, the main
conclusion of our study is that under conditions where the amountknockout mice.
llenge. Data represent means±SEM of 8-9 mice per group. * p<0.05, ** p<0.01 versus
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under low HDL conditions in mice and low LDL conditions in
humans, adrenal HMG-CoA reductase is of importance to generate
sufﬁcient cholesterol to maintain a proper steroidogenesis rate.
Furthermore, given the high similarity in the glucocorticoid insuf-
ﬁciency phenotype of LDL deﬁcient humans [11e13] and HDL
deﬁcient mice [3,5], we do value that our ﬁndings have a high
translational power. As such, we regard it important to determine
the adrenal function in patients treated with aggressive statin
(combination) treatments aimed at inducing relatively low LDL-
cholesterol levels to identify a potential risk of developing gluco-
corticoid insufﬁciency.
In conclusion, we have shown that simvastatin treatment ag-
gravates the glucocorticoid insufﬁciency associated with hypo-
cholesterolemia. Our data (1) supply novel proof for the hypothesis,
originally formulated by Plump et al. [3], that HMG-CoA reductase
activity is increased under hypocholesterolemic conditions to
compensate for the loss of lipoproteins as external cholesterol
source and maintain the adrenal steroidogenic capacity and (2)
imply that it might be important to monitor the adrenal function in
humans subjected to high dose statins in (combination) therapies
aimed at achieving sub-physiological LDL-cholesterol levels, as
these may potentially execute a negative impact on the glucocor-
ticoid function in humans.
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